Related references
Note: Only part of the references are listed.Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study
Takashi Wada et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2021)
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2021)
Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism
Fumitoshi Satoh et al.
HYPERTENSION RESEARCH (2021)
Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
Sadayoshi Ito et al.
HYPERTENSION RESEARCH (2021)
Efficacy and safety of esaxerenone in patients with hypertension and concomitant heart failure
Takashi Naruke et al.
HYPERTENSION RESEARCH (2021)
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Gerasimos Filippatos et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study
Sadayoshi Ito et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2021)
Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study
Kazuomi Kario et al.
AMERICAN JOURNAL OF HYPERTENSION (2021)
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial
John G. F. Cleland et al.
EUROPEAN HEART JOURNAL (2021)
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal et al.
EUROPEAN HEART JOURNAL (2021)
Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
Akifumi Kurata et al.
ADVANCES IN THERAPY (2020)
Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
Andrew Whittaker et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150)
Mizuki Takahashi et al.
FEBS LETTERS (2020)
Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
Matteo Serenelli et al.
JACC-HEART FAILURE (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure
Masayoshi Yamamoto et al.
HEART AND VESSELS (2019)
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment
Roland Heinig et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2019)
Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
Sadayoshi Ito et al.
JOURNAL OF HUMAN HYPERTENSION (2019)
Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study
Hiroshi Itoh et al.
HYPERTENSION RESEARCH (2019)
Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension
Hiromi Rakugi et al.
HYPERTENSION RESEARCH (2019)
MRAs in Elderly HF Patients Individual Patient-Data Meta-Analysis of RALES, EMPAHSIS-HF, and TOPCAT
Joao Pedro Ferreira et al.
JACC-HEART FAILURE (2019)
Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects
Manabu Kato et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
Bryan Williams et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro
Michael Gerisch et al.
DRUG METABOLISM AND DISPOSITION (2018)
Adverse Effects of Mineralocorticoid Receptor Antagonist Administration
Manolis S. Kallistratos et al.
CURRENT PHARMACEUTICAL DESIGN (2018)
Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys
Makiko Yamada et al.
XENOBIOTICA (2017)
Mineralocorticoid receptor antagonists: 60 years of research and development
Peter Kolkhof et al.
JOURNAL OF ENDOCRINOLOGY (2017)
Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status
Graeme Eisenhofer et al.
CLINICA CHIMICA ACTA (2017)
Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
Li-Jing Sun et al.
JOURNAL OF DIABETES INVESTIGATION (2017)
Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review
Alison M. Layton et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Mass Spectrometry-Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism
Graeme Eisenhofer et al.
CLINICAL CHEMISTRY (2016)
Mineralocorticoid receptor antagonists - pharmacodynamics and pharmacokinetic differences
Jun Yang et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos et al.
EUROPEAN HEART JOURNAL (2016)
CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats
Kiyoshi Arai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies
Khagendra Dahal et al.
AMERICAN JOURNAL OF HYPERTENSION (2015)
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
Kiyoshi Arai et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats
Kiyoshi Arai et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone
Mitja Lainscak et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
Larbi Amazit et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Bryan Williams et al.
LANCET (2015)
Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study
Gilles Montalescot et al.
EUROPEAN HEART JOURNAL (2014)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt et al.
EUROPEAN HEART JOURNAL (2013)
Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function Analyses of the EMPHASIS-HF Study Subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)
Romain Eschalier et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
Lars Baerfacker et al.
CHEMMEDCHEM (2012)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Endogenous inhibitors (GALFs) of 11β-hydroxysteroid dehydrogenase isoforms 1 and 2:: Derivatives of adrenally produced corticosterone and cortisol
D. J. Morris et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2007)
Effect of spironolactone on blood pressure in subjects with resistant hypertension
Neil Chapman et al.
HYPERTENSION (2007)
Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans
CS Cook et al.
DRUG METABOLISM AND DISPOSITION (2003)
Share Paper
